Objective. The objective of this study was to assess the diagnostic value of anti-Ro52/60 antibodies by immunodot in patients with suspected SS.
Introduction
SS is a systemic autoimmune disorder associated with exocrine gland dysfunction and extraglandular organ involvement. American-European Consensus Group (AECG) criteria are widely used to assess the diagnosis of SS, and the presence of anti-SSA antibodies (Ro52/ Ro60) constitute a mandatory criterion, particularly in patients with a negative salivary gland biopsy [1] . However, the AECG criteria do not identify a reference method for the detection of anti-SSA/SSB antibodies.
Different tests are available to detect anti-SSA/SSB antibodies, such as ELISA, double immunodiffusion, Western blot and addressable laser bead assay. The frequency of anti-SSA/SSB antibody detection varies according to the diagnostic test [2, 3] . Combining different methods of detection could help in making a timely SS diagnosis [3, 4] . SSA antigens consist of two different proteins: Ro60 (native SSA) and Ro52 (identified as TRIM21). Spreading of the autoimmune response could occur between these two epitopes, which form the ribonucleoprotein particle and could underline the concordance of anti-Ro52 and anti-Ro60 antibodies. The different methods available for the detection of anti-SSA antibodies could differ in their capacity to recognize anti-Ro60 and anti-Ro52 antibodies. The benefit of the detection of anti-Ro52/60 antibodies separately in autoimmune diseases and their clinical profile is still debated. Using the Luminex technique, the anti-Ro52 antibodies failed to reach discriminatory diagnostic value in patients with different autoimmune disorders, while another report using the immunodot method showed a high prevalence in the presence of pulmonary involvement and myositis [5, 6] . Among ANA-positive patients with primary SS, the prevalence of anti-Ro52 was found to be 37% and was shown to help classify the SS diagnosis [7] . The additional anti-SSA (Ro52/Ro60) antibodies by immunodot could be identified in 35% of ANA-positive patients with negative immunodiffusion and 43% of negative ELISAs [3, 4] . In patients with suspected SS with negative anti-SSA/SSB antibodies by ELISA, the value of detection of anti-Ro52/60 antibodies using immunodot as a second line after negative ELISA has not yet been assessed.
The aim of this study was (i) to investigate the diagnostic value of anti-Ro52/60 antibodies by immunodot in patients with suspected SS without anti-SSA (Ro52/60)/SSB antibodies by ELISA and (ii) to characterize the clinical and biological profile of patients with dry eye/mouth syndrome and positive anti-Ro52/60 antibodies detected by immunodot.
Methods

Inclusion criteria
This study was conducted in two university internal medicine and pneumology departments between 2008 and 2012. In this retrospective study patients were selected on the basis of the following criteria: (i) suspected SS with subjective and/or objective dry eye/mouth syndrome, (ii) absence of other obvious etiologies for dry eye/mouth syndrome, (iii) absence of antinuclear anti-SSA and anti-SSB antibodies by ELISA and (iv) determination of anti-Ro52/60 antibodies by immunodot (Euroimmun, Germany). Ethical approval was not required for this study. Patients were informed at entry into the database that they might be included in clinical research studies and blood could be taken. Patients who declined to be included in clinical research studies were excluded.
Data collection
One physician (A.M.) used a standard form to record the data of patients. The data included the patients' general characteristics, Schirmer's test and salivary gland biopsy results and assessment of the Chisholm score. Laboratory data included standard tests, serum gamma globulins, CH50, C3, C4, RF, protein immunofixation, ANAs, serum cryoglobulin, aPL, ANCA, CRP, ESR and HIV and HCV serologies. The presence of interstitial lung disease (ILD) was defined on high-resolution CT of the chest. For patients with ILD, the results of pulmonary function tests, arterial blood gas, bronchoalveolar lavage fluid and highresolution chest CT images were recorded. The diagnosis of SS was assessed according to the AECG for each patient and included either the presence of a salivary gland biopsy or the detection of anti-Ro52/60 antibodies by immunodot. Other autoimmune diseases were diagnosed according to the usual international criteria for classification (i.e. ACR criteria for SLE).
Anti-SSA antibody detection
The detection of ANA and anti-SSA/SSB was performed by one of the authors (P.N.-R.) in the same university laboratory, using indirect immunofluorescence on Hep-2 cells and a modified ELISA technology with recombinant antigens for Ro52, Ro60 and SSB (Elia, ThermoFisher, Friburg, Germany), respectively. The determination of anti-SSA (Ro52/60) antibodies by immunodot was assessed with a line immunoassay (ANA Profile 3, Euroimmun AG, Lubeck, Germany), which identifies 15 different autoantibodies and used purified Ro60 and recombinant Ro52, according to the recommendations of the assay.
Statistical analysis
The data are presented as medians with interquartile ranges (IQRs) for continuous variables and numbers with percentages for qualitative variables. Fisher's exact test was used to compare qualitative variables, while t-test and non-parametric MannWhitney test were used for continuous variables according to the distribution of the parameters. P < 0.05 was considered significant. Statistical analyses were conducted using GraphPad Prism (GraphPad Software, La Jolla, CA, USA, 2007).
Results
Patients with dry eye/mouth syndrome without ILD (from the Department of Internal Medicine) Thirty-nine patients [median age 51 years (IQR 4662 years); seven males] with dry eye/mouth syndrome without ILD were included. Their general characteristics are in Table 1 . In these patients, 8 (21%) fulfilled the AECG criteria with a positive salivary biopsy. Anti-Ro52/ 60 antibodies were present in 8/39 cases (21%); considering anti-Ro52/60 antibody positivity, 6 (15%) additional cases could be classified as SS (supplementary Fig. S1 , available at Rheumatology Online). Among these six patients, primary SS was diagnosed in five cases and SS associated with RA was diagnosed in the remaining case.
Patients with ILD (from the Department of Pneumology)
Forty-five patients with dry eye/mouth syndrome and ILD were analysed (Table 1 ). In these patients only 2 (4%) fulfilled the AECG criteria without anti-Ro52/60 antibodies. In those patients with ILD and dry eye/mouth syndrome with negative ELISA, 10 (22%) had positive anti-Ro52/60 antibodies. Considering anti-Ro52/60 antibody positivity identified 4 (8%) additional patients (supplementary Fig. S2 , available at Rheumatology Online): 3 associated with SS and 1 primary SS. For the six patients with antiRo52/60 antibodies with insufficient AECG criteria, all had subjective dry eye/mouth syndrome, with objective xerophthalmia in two cases, but failed to have exploration of the objective xerostomia.
In patients with ILD, the presence of a Chisholm score 53, or AECG criteria without anti-Ro52/60, and other extraglandular symptoms were less frequent than in patients without pulmonary involvement, whereas the frequency of anti-Ro52/60 antibodies was similar to that observed in patients without ILD (Table 1 ). Comparing patients with ILD and anti-Ro52/60 (n = 10) and patients with ILD without anti-Ro52/62 (n = 35) revealed a tendency towards increased ESR, higher gamma globulin levels and increased steroid use in patients with anti-Ro52/60 (P = 0.07), without any difference in pulmonary characteristics.
All patients
Eighty-four patients [median age 62 years (IQR 5272 years); 35 males] were included ( Table 2 ). All patients had at least subjective and/or objective dry Values are median with interquartile range or n (%). *P < 0.05; **P = 0.05.
www.rheumatology.oxfordjournals.org eye/mouth syndrome with suspected primary SS. Extraglandular symptoms were skin involvement (purpura, Raynaud's phenomena, urticaria; n = 23), peripheral neuropathy (n = 9), joint involvement (arthralgias and/or arthritis; n = 39) and ILD (n = 45). The median ANA titre was 80 (0160). ELISA detection of anti-SSA (Ro52 or Ro60)/ SSB antibodies gave negative results in all patients. AntiRo52/60 antibodies by immunodot were detected in 18 (20%) cases, with isolated anti-Ro52 antibodies (n = 15), isolated anti-Ro60 antibodies (n = 2) and anti-Ro52 + Ro60 antibodies (n = 1). Associated autoantibodies were detected in four cases and were all anti-Jo1 antibodies. Antisynthetase syndrome was associated in 6/84 cases, with 4 cases with previously determined anti-Jo1 antibodies that were confirmed in all 4 cases by immunodot. Among all 84 patients, AECG criteria for SS were fulfilled in 10 patients (12%) in the presence of positive salivary gland biopsies (supplementary Fig. S3 , available at Rheumatology Online). Among the remaining patients with a negative biopsy not fulfilling the AECG criteria, 16 (19%) had anti-Ro52/60 antibodies by immunodot and 10 (12%) fulfilled the AECG criteria when including the presence of Ro52/60 antibodies (anti-Ro52 in 8 cases, anti-Ro60 in 2 cases and anti-Ro52 + Ro60 in 1 case). Among these 10 additional SS cases, the syndrome was primary in 6 (60%) cases.
Other autoimmune diseases could be diagnosed in 19 cases, including RA (n = 7), antisynthetase syndrome (n = 6), pernicious anaemia (n = 2), SLE (n = 2), idiopathic thrombocytopenic purpura and polyarteritis nodosa (n = 1 each). Patients with negative anti-Ro52/60 antibodies and without another autoimmune disease were finally considered as sicca syndrome (n = 13), idiopathic ILD (n = 30) or other diseases (Q fever, Bartonella henselae infection, congenital hypoparathyroidism, primary hyperparathyroidism; n = 1 each). Values are median with interquartile range or n (%). *P < 0.05; **P = 0.07.
A comparison of patients with and without anti-Ro52/ 60 antibodies revealed no differences in the presence of extraglandular involvement or standard biological data (Table 2) . Only ESR and gamma globulin levels tended to be higher in patients with antibodies. Steroid use and associated autoimmune disease were more common in patients with positive anti-Ro52/60 antibodies (P < 0.05). Similarly, comparing patients with SS according to a positive salivary gland biopsy to patients with AECG criteria including positive antiRo52/60 antibodies (n = 10, each) revealed only higher gamma globulin levels in the second subgroup (P < 0.05).
Discussion
This is the first study to investigate the diagnostic value of immunodot for the detection of anti-Ro52/60 antibodies to confirm SS in patients with a clinical suspicion of SS and the absence of anti-SSA/SSB antibodies by ELISA. We show that immunodot identifies the presence of anti-Ro52/60 antibodies in slightly more than 20% of these patients and that 12% could be classified with SS according to the AECG criteria.
The AECG criteria consider the presence of anti-SSA/ SSB antibodies as a mandatory criterion, but the method for antibody detection is not specified [1] . ELISA is the preferred method for the initial screening, even in patients with negative ANA. Previous studies showed that anti-SSA antibodies could be detected in 3050% of ANAnegative patients using ELISA [8] . Using semi-quantitative ELISA in patients with confirmed SS and positive ANA, anti-Ro52 antibodies were detected in 12% of antiRo60-negative patients with a positive salivary gland biopsy [7] , a value very similar to our results, as 20% of patients with a positive salivary gland biopsy had antiRo52 antibodies with immunodot in the present study. As many as 60% of these additional cases of SS were primary, mostly diagnosed in the subgroup of patients with ILD. Another study in patients with confirmed SS and positive ANA showed that anti-Ro52 by immunodot was the most frequently detected autoantibody after ANA [9] . Thus separate anti-Ro52/60 antibody screening by immunodot could be considered in the SS criteria as an alternative to anti-SSA/SSB screening by ELISA. Recently new provisional ACR classification criteria for SS emphasize the importance of anti-SSA/SSB antibodies, even in patients without dry eye/mouth syndrome [10] . The use of immunodot to detect these antibodies in selected patients not fulfilling the new ACR criteria could be interesting to evaluate.
The clinical and prognostic value of anti-Ro52/60 antibodies in SS remains unknown. In one study, patients with SS with anti-Ro52 antibodies were found to have more severe parotid enlargement, increased gamma globulin levels and cytopenia [7] . In our study, patients with SS with anti-Ro52 antibodies had increased gamma globulin levels and steroid use. In patients with anti-Jo1-positive antisynthetase syndrome, the detection of anti-Ro52/60 antibodies was associated with decreased survival and associated malignancy [11] . Interestingly, maternal anti-Ro52/60 levels are more important in the presence of cardiac neonatal lupus and higher levels could be associated with more aggressive SS, but the immunodot assay does not allow a quantitative determination [12] . Ro-52 is an IFN-inducible protein, and B cell activating factor (BAFF) expression is regulated by IFNs and could be indirectly regulated by Ro-52. Ro52-deficient mice develop signs of systemic lupus, with autoantibodies and hypergammaglobulinaemia [13] . Hypergammaglobulinaemia was more common in anti-Ro52-positive patients in our study and could implicate IFN-and BAFF-induced pathways in these patients.
The presence of anti-Ro52 antibodies was previously shown to be associated with the presence of ILD in patients with connective diseases, mainly the antisynthetase syndrome [6, 14] . In our study, immunodot diagnosed associated SS, but was not useful for the detection of additional anti-Jo1 antibodies. Previously it was shown that in patients with idiopathic ILD, the detection of anti-SSA/SSB antibodies is associated with more frequent subjective dry eye/mouth syndrome, but only a minority of patients fulfilled the AECG criteria for SS and extrarespiratory signs were exceedingly rare [15] . Considering the low frequency of objective dry eye/mouth syndrome, high Chisholm score and extrarespiratory features in patients with ILD, anti-Ro52/60 screening with immunodot could be of interest in patients with ILD and dry eye/mouth symptoms.
This study has some limitations that should be mentioned, including its retrospective design and the relatively limited number of patients studied. However, we believe our study is relevant for real-life assessment of dry eye/mouth syndrome, as previous studies determined the anti-Ro52 value in ANA-positive patients with confirmed SS or in the context of general ANA determination [16] . Even mostly associated SS have been noted in patients with ILD, a small number of patients and some missing data could raise the need of prospective study in this subgroup of patients. Although antiRo52 antibodies have been associated with more frequent liver and muscle impairment in SS, the prognostic value of these antibodies in SS remains to be determined [9] .
Conclusion
In patients with dry eye/mouth syndrome without anti-SSA (Ro52 and Ro60)/SSB antibodies by ELISA, the detection of anti-Ro52/60 antibodies with another method could help in the diagnosis of SS. In patients with ILD, the lower frequency of a Chisholm score 53 and of extraglandular symptoms enhances the interest of antiRo52/60 screening in the presence of dry eye/mouth syndrome. As immunodot is costly and time consuming, its use should be restricted to patients with subjective and objective dry eye/mouth syndrome with negative ELISA testing.
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Rheumatology key messages
. In dry eye/mouth syndrome without anti-SSA antibodies, anti-Ro52/60 antibodies by immunodot aid in the diagnosis of SS. . Anti-Ro52/60 antibodies by immunodot could aid in the diagnosis of ILD related to SS.
